- 4-Week # shares bought: 16,500
- 4-Week # shares sold: 19,064
- 12-Week # shares bought: 16,500
- 12-Week # shares sold: 29,064
- 24-Week # shares bought: 16,500
- 24-Week # shares sold: 29,064
The Canadian marijuana market is poised for growth as the number of registered patients continues grows and as licensed producers find innovative ways to create value for its shareholders.
GW Pharmaceuticals has developed cannabis-based therapies for treating epilepsy and multiple sclerosis.
Jim Cramer finds reasons to like AEP, AMGN, DOW and HEI.
This rally isn't just about Trump, Cramer says. He thinks investors are cheering the economic outlook.